Yeast based small molecule screen for inhibitors of SARS-CoV

PLoS ONE

Volumn 6, Issue 12, 2011, Pages

  Frieman, Matthew ^a   Basu, Dipanwita ^b   Matthews, Krystal ^a   Taylor, Justin ^a   Jones, Grant ^a   Pickles, Raymond ^c   Baric, Ralph ^d   Engel, Daniel A ^b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d IL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; NSC 112796; NSC 158011; NSC 158362; NSC 1614; NSC 221736; PAPAIN LIKE PROTEASE; PROTEINASE; UNCLASSIFIED DRUG; GREEN FLUORESCENT PROTEIN;

ANIMAL CELL; ARTICLE; CELL CULTURE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG CYTOTOXICITY; DRUG DETERMINATION; DRUG DEVELOPMENT; DRUG SCREENING; DRUG STRUCTURE; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; INCIDENCE; INFLUENZA VIRUS; MAMMAL CELL; MORTALITY; NONHUMAN; PHENOTYPE; SACCHAROMYCES CEREVISIAE; SARS CORONAVIRUS; VIROGENESIS; VIRUS REPLICATION; YEAST; YEAST CELL; ANIMAL; CELL STRAIN HEK293; CERCOPITHECUS; CULTURE MEDIUM; CYTOLOGY; DRUG DESIGN; EPITHELIUM CELL; GENETICS; IN VITRO STUDY; METABOLISM; METHODOLOGY; MOLECULAR CLONING; ORTHOMYXOVIRUS; PHARMACEUTICS; PROTEIN BINDING; TRACHEA; VERO CELL; VIROLOGY;

ANIMALS; ANTIVIRAL AGENTS; CERCOPITHECUS AETHIOPS; CLONING, MOLECULAR; CULTURE MEDIA; DRUG DESIGN; EPITHELIAL CELLS; GREEN FLUORESCENT PROTEINS; HEK293 CELLS; HUMANS; ORTHOMYXOVIRIDAE; PHENOTYPE; PROTEIN BINDING; SACCHAROMYCES CEREVISIAE; SARS VIRUS; TECHNOLOGY, PHARMACEUTICAL; TRACHEA; VERO CELLS;

EID: 82555170562     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0028479     Document Type: Article

References (22)

1. Katz JM, Lu X, Frace AM, Morken T, Zaki SR, et al. (2000) Pathogenesis of and immunity to avian influenza A H5 viruses. Biomed Pharmacother 54: 178-187.
2. Gee MH, Gottlieb JE, Albertine KH, Kubis JM, Peters SP, et al. (1990) Physiology of aging related to outcome in the adult respiratory distress syndrome. J Appl Physiol 69: 822-829.
3. Sheng WH, Chiang BL, Chang SC, Ho HN, Wang JT, et al. (2005) Clinical manifestations and inflammatory cytokine responses in patients with severe acute respiratory syndrome. J Formos Med Assoc 104: 715-723.
4. Chen J, Subbarao K, (2007) The Immunobiology of SARS*. Annu Rev Immunol 25: 443-472.
5. Cheung OY, Chan JW, Ng CK, Koo CK, (2004) The spectrum of pathological changes in severe acute respiratory syndrome (SARS). Histopathology 45: 119-124.
6. Chong PY, Chui P, Ling AE, Franks TJ, Tai DY, et al. (2004) Analysis of deaths during the severe acute respiratory syndrome (SARS) epidemic in Singapore: challenges in determining a SARS diagnosis. Archives of pathology & laboratory medicine 128: 195-204.
7. Nicholls JM, Poon LL, Lee KC, Ng WF, Lai ST, et al. (2003) Lung pathology of fatal severe acute respiratory syndrome. Lancet 361: 1773-1778.
8. Peiris JS, Lai ST, Poon LL, Guan Y, Yam LY, et al. (2003) Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet 361: 1319-1325.
9. Donnelly CA, Ghani AC, Leung GM, Hedley AJ, Fraser C, et al. (2003) Epidemiological determinants of spread of causal agent of severe acute respiratory syndrome in Hong Kong. Lancet 361: 1761-1766.
10. Drosten C, Gunther S, Preiser W, van der Werf S, Brodt HR, et al. (2003) Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med 348: 1967-1976.
11. Chan PK, Ip M, Ng KC, Rickjason CW, Wu A, et al. (2003) Severe acute respiratory syndrome-associated coronavirus infection. Emerging infectious diseases 9: 1453-1454.
12. Chan-Yeung M, Xu RH, (2003) SARS: epidemiology. 8 (Suppl) Respirology: S9-14.
13. Guan Y, Zheng BJ, He YQ, Liu XL, Zhuang ZX, et al. (2003) Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China. Science 302: 276-278.
14. Harcourt BH, Jukneliene D, Kanjanahaluethai A, Bechill J, Severson KM, et al. (2004) Identification of severe acute respiratory syndrome coronavirus replicase products and characterization of papain-like protease activity. Journal of virology 78: 13600-13612.
15. Barretto N, Jukneliene D, Ratia K, Chen Z, Mesecar AD, et al. (2005) The papain-like protease of severe acute respiratory syndrome coronavirus has deubiquitinating activity. J Virol 79: 15189-15198.
16. Basu D, Walkiewicz MP, Frieman M, Baric RS, Auble DT, et al. (2009) Novel influenza virus NS1 antagonists block replication and restore innate immune function. J Virol 83: 1881-1891.
17. Ziebuhr J, (2004) Molecular biology of severe acute respiratory syndrome coronavirus. Curr Opin Microbiol 7: 412-419.
18. Walkiewicz MP, Basu D, Jablonski JJ, Geysen HM, Engel DA, (2011) Novel inhibitor of influenza non-structural protein 1 blocks multi-cycle replication in an RNase L-dependent manner. The Journal of general virology 92: 60-70.
19. Zhang L, Peeples ME, Boucher RC, Collins PL, Pickles RJ, (2002) Respiratory syncytial virus infection of human airway epithelial cells is polarized, specific to ciliated cells, and without obvious cytopathology. J Virol 76: 5654-5666.
20. Sims AC, Baric RS, Yount B, Burkett SE, Collins PL, et al. (2005) Severe acute respiratory syndrome coronavirus infection of human ciliated airway epithelia: role of ciliated cells in viral spread in the conducting airways of the lungs. J Virol 79: 15511-15524.
21. Frieman M, Ratia K, Johnston RE, Mesecar AD, Baric RS, (2009) SARS Coronavirus Papain-Like Protease Ubiquitin-like domain and Catalytic domain regulate antagonism of IRF3 and NFkB signaling. J Virol. 2009 Jul; 83 (13): 6689-705.
22. Daniel JA, Yoo J, Bettinger BT, Amberg DC, Burke DJ, (2006) Eliminating gene conversion improves high-throughput genetics in Saccharomyces cerevisiae. Genetics 172: 709-711.